{"type":"trials","record":{"id":41961,"source_id":"clinicaltrials-gov","external_id":"NCT03891875","title":"ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA","brief_summary":"A randomized, double-masked, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of elamipretide in subjects with Age-Related Macular Degeneration with non-central Geographic Atrophy.","overall_status":"Completed","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Stealth BioTherapeutics Inc.","enrollment":176,"countries":["United States"],"start_date":"2019-03-27","completion_date":"2022-04-14","last_update_date":"2024-07-12","source_url":"https://clinicaltrials.gov/study/NCT03891875","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"ReCLAIM-2","age_range":"55 Years","comparator":"Placebo","organization":"Stealth BioTherapeutics Inc.","interventions":["Subcutaneous elamipretide through the elamipretide delivery system","Subcutaneos placebo through the elamipretide delivery system"],"registry_source":"ClinicalTrials.gov","outcome_measures":["LL BCVA Score Change From Baseline — Baseline and Weeks 4, 8, 12, 24, 36, 48","GA Area Change From Baseline by OCT — Baseline and Weeks 12, 24, 36, 48","LL RA Change From Baseline — Baseline and Weeks 4,12, 36, 48","BCVA Change From Baseline — Baseline and Weeks 4, 8, 12, 24, 36, 48","GA Area as Measured by Fundus Autofluorescence (FAF) Change From Baseline — Baseline and Weeks 12, 24, 36, 48"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":true},"controlled_terms":["Age-related Macular Degeneration","Subcutaneous elamipretide through the elamipretide delivery system","Subcutaneos placebo through the elamipretide delivery system"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct03891875","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2019-03-27 to 2022-04-14","comparator":"Placebo","confidence":"structured-source","population":"ALL · 55 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.900Z","intervention":["Subcutaneous elamipretide through the elamipretide delivery system","Subcutaneos placebo through the elamipretide delivery system"],"participants":176,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["LL BCVA Score Change From Baseline — Baseline and Weeks 4, 8, 12, 24, 36, 48","GA Area Change From Baseline by OCT — Baseline and Weeks 12, 24, 36, 48","LL RA Change From Baseline — Baseline and Weeks 4,12, 36, 48","BCVA Change From Baseline — Baseline and Weeks 4, 8, 12, 24, 36, 48","GA Area as Measured by Fundus Autofluorescence (FAF) Change From Baseline — Baseline and Weeks 12, 24, 36, 48"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41961","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}